The Quality Lowdown: The Effort Required To Stem Substandard, Illegitimate, Unapproved Drugs
Executive Summary
As stakeholders in the US pharmaceutical distribution chain prepare to coordinate against suspect drugs, the world’s leading inspectorates collaborate on good distribution practices.
You may also be interested in...
Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
Meeting 10-Year DSCSA Serialization Mandate Requires Industry Big Push In Final Year
HDA finds much progress to report in seventh annual Serialization Readiness Survey, but quite a lot of work remains for many drug manufacturers and distributors if they are to meet November 2023 compliance deadline.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.